Over-representation of bcr3 subtype of PML/RARα fusion gene in APL in Indian patients

Annals of Hematology

Volumn 84, Issue 12, 2005, Pages 781-784

  Sazawal, Sudha ^a   Hasan, Syed Khizer ^a   Dutta, Pankhi ^a   Kumar, Bijender ^a   Kumar, Rajat ^a   Kumar, Lalit ^a   Choudhry, V P ^a   Saxena, Renu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute promyelocytic leukemia; Hematological remission; Molecular remission; PML RAR isoform; Real time PCR; Reverse transcription polymerase chain reaction (RT PCR)

Indexed keywords

DAUNORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BCR3; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; FEMALE; GENE OVEREXPRESSION; HUMAN; INDIA; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INDIA; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PREVALENCE; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-BCR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 29444433955     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1095-4     Document Type: Article

References (12)

1. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanathan D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH (1997) Association of PML/RARα fusion mRNA type with pretreatment hematological characteristics but not treatment outcome in acute promyelocytic leukaemia: An intergroup molecular study. Blood 90:1656-1663 9269786
2. Gonzalez M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstien R, Calasanz MJ, Gomez-Casares MT, Villegas A, Margaun I, Roman J, Martin C, Rayon C, Deben G, Tormo M, Diaz-Mediavilla J, Esteve J, Gonzales-San Miguel J, Rivas C, Perez-Equiza K, Garcia-Sanz R, Capote FJ, Ribera JM, Arias J, Laon A, Snaz MA (2001) Pretreatment characteristic and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARA isoforms; a study of the PETHEMA group. Br J Haematol 114:9-103 10.1046/j.1365-2141.2001.02915.x
3. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S (1993) Acute promeylocytic leukaemia: Clinical relevance of two major PML/RAR alpha isoform and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 82:1264-1269 8394752
4. Gupta V, Yi Q, Brandwein J, Chun K, Lipton JH, Messner H, Schuh AC, Wells RA, Minden MD, Kamel-Reid S (2004) Clinico-biological feature and prognostic significance of PML/RARα isoform in adult patients with acute promeylocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy. Leuk Lymphoma 45:469-480 10.1080/10428190310001617295
5. Tallman MS, Nabhan C, Feusner JH, Rowe JM (2002) Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 99:759-767 10.1182/ blood.V99.3.759
6. Chomczynski N, Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocynate-phenol-chloroform extraction. Anal Biochem 162:156-159 10.1016/0003-2697(87)90021-2
7. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheately K, Goldstone A, Burnett A, Solomon E (1996) Establishing the presence of the t(15:17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 94:557-573 8790159
8. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain ID, Fenaux P, Degos L, Vidaud M, Chomienne C (2000) Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15:17) translocation using real-time RT-PCR. Leukemia 14:324-328 10.1038/ sj.leu.2401652
9. Fenaux P, Chastang C, Chevert S, Sanz M, Dombert H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (1999) A randomized comparison of all tran retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia: The European APL group. Blood 94(4):1192-1200 10438706
10. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Jordi Esteve, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F (2000) Definition of relapse risk and role of nonanthracyclin drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253 10942364
11. Dong S, Geng JP, Tong JH, Chai JR, Sun GL, Chen SR, Wang ZY, Larsen CJ, Berger R, Chen SJ, Chen Z (1993) Breakpoint cluster of PML gene in acute promyelocytic leukaemia: Primary structure of he reciprocal products of the PML-RARα gene in a patient with t(15:17). Genes Chromosomes Cancer 8:133-139
12. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Vecchio LD, Tabilio A, Avvisati G, Basso G, LoCoco F (1998) Immunophenotyping of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome: A cooperative Italian study on 196 cases. Br J Haematol 102:1035-1041 10.1046/j.1365-2141.1998.00871.x